6,698 results on '"Chan, At"'
Search Results
2. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
3. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
4. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML
5. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
6. Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
7. New insights into the biology of T-cell lymphomas
8. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
9. Innovations in RNA therapy for hemophilia
10. Single-cell landscape of idiopathic multicentric Castleman disease in identical twins
11. Prevalence and significance of DDX41 gene variants in the general population
12. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
13. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura
14. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
15. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
16. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
17. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
18. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
19. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
20. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS
21. A study of ruxolitinib response–based stratified treatment for pediatric hemophagocytic lymphohistiocytosis
22. Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia
23. Impaired p47phox phosphorylation in neutrophils from patients with p67phox-deficient chronic granulomatous disease
24. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
25. A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma
26. Therapeutic options for relapsed/refractory mantle cell lymphoma
27. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML
28. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
29. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
30. Motive and opportunity: MYCrearrangements in high-grade B-cell lymphoma with MYCand BCL2rearrangements (an LLMPP study)
31. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1
32. Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm
33. Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients
34. Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry
35. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
36. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
37. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma
38. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
39. Pembrolizumab: a key for some, but not all, HL
40. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation
41. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
42. Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments
43. Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation
44. A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
45. Uncovering the mystery of opposite circadian rhythms between mouse and human leukocytes in humanized mice
46. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
47. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
48. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
49. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
50. Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.